{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:27:24Z","timestamp":1778758044286,"version":"3.51.4"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,21]]},"abstract":"<jats:p>\n                    The purpose of this study was to analyze the impact of circulating immune cells before and after chemotherapy on the prognosis of patients with advanced pancreatic adenocarcinoma (PAC). Data were collected from 74 advanced PAC patients with post-chemotherapy, retrieved from the Affiliated Hospital of Nantong University database in Jiangsu. Based on the cutoff values of circulating CD4+ and CD8+ T cells before and after chemotherapy, the aforementioned patients were divided into high- and low-level groups. The impact of the expression levels of blood immune cells before and after chemotherapy on patient prognosis was analyzed separately. For both pre- and post-treatment circulating CD4+ and CD8+ T cells, patients in the high expression group had significantly better progression-free survival and overall survival than those in the low expression group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). The results of this study show that high circulating immune cells are positively associated with better prognosis in patients with advanced PAC receiving chemotherapy and may become a new prognostic indicator for PAC treatment.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000046077","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:02:20Z","timestamp":1764169340000},"page":"e46077","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The effect of circulating CD4+ and CD8+ T cells on the prognosis in advanced postoperative pancreatic adenocarcinoma patients who received chemotherapy"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5126-7199","authenticated-orcid":false,"given":"Qingqing","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Pathology, Affiliated Hospital 2 of Nantong University, Nantong, Jiangsu Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Jiading District Anting Hospital of Shanghai, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Si","sequence":"additional","affiliation":[{"name":"Department of Pathology, Affiliated Hospital 2 of Nantong University, Nantong, Jiangsu Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jibin","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260514","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"R2-20260514","first-page":"15","article-title":"Cancer statistics, 2021.","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-20260514","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges.","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"R4-20260514","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.pan.2022.06.005","article-title":"Ecoevolutionary biology of pancreatic ductal adenocarcinoma.","volume":"22","author":"Raja Arul","year":"2022","journal-title":"Pancreatology"},{"key":"R5-20260514","first-page":"1234","article-title":"From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer.","volume":"15","author":"Smith","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R6-20260514","doi-asserted-by":"crossref","first-page":"893177","DOI":"10.3389\/fimmu.2022.893177","article-title":"Transcriptome analysis of tumor-infiltrating lymphocytes identifies NK cell gene signatures associated with lymphocyte infiltration and survival in soft tissue sarcomas.","volume":"13","author":"Judge","year":"2022","journal-title":"Front Immunol"},{"key":"R7-20260514","doi-asserted-by":"crossref","first-page":"16606","DOI":"10.1038\/s41598-023-43946-6","article-title":"Expression of polymeric immunoglobulin receptor (PIGR) and the effect of PIGR overexpression on breast cancer cells.","volume":"13","author":"Asanprakit","year":"2025","journal-title":"Sci Rep"},{"key":"R8-20260514","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy.","volume":"9","author":"Yi","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"R9-20260514","first-page":"123","article-title":"Mobilization of CD8(+) T cells via CXCR4 blockade facilitates PD-1 checkpoint therapy in human pancreatic cancer.","volume":"45","author":"Brown","year":"2023","journal-title":"J Immunother"},{"key":"R10-20260514","first-page":"471","article-title":"Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: current research and future perspective.","volume":"11","author":"Zhang","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"R11-20260514","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1158\/1078-0432.CCR-21-3452","article-title":"Facts and hopes in immunotherapy of pancreatic cancer.","volume":"28","author":"Bockorny","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R12-20260514","doi-asserted-by":"crossref","first-page":"e00463","DOI":"10.14309\/ctg.0000000000000463","article-title":"Chronic pancreatitis is a risk factor for pancreatic cancer and incidence increases with duration of disease: a systematic review and meta-analysis.","volume":"13","author":"Gandhi","year":"2022","journal-title":"Clin Transl Gastroenterol"},{"key":"R13-20260514","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.3748\/wjg.v27.i25.3825","article-title":"Autoimmune pancreatitis and pancreatic cancer: epidemiological aspects and immunological considerations.","volume":"27","author":"Poddighe","year":"2025","journal-title":"World J Gastroenterol"},{"key":"R14-20260514","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging.","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R15-20260514","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells.","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res"},{"key":"R16-20260514","first-page":"124","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"101","author":"Eisenhauer","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"R17-20260514","first-page":"869","article-title":"The application of patient-reported outcome measures in cancer clinical trials: a review of recent research by the academic and research organisation of the national cancer research institute (UK).","volume":"149","author":"Smith","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"R18-20260514","first-page":"1234","article-title":"The importance of overall survival in advanced breast cancer clinical trials.","volume":"35","author":"Doe","year":"2023","journal-title":"J Clin Oncol"},{"key":"R20-20260514","first-page":"345","article-title":"Pancreatic cancer and immunotherapy: a clinical overview.","volume":"12","author":"Smith","year":"2023","journal-title":"J Cancer Ther"},{"key":"R21-20260514","first-page":"1029","article-title":"The tumour microenvironment in pancreatic cancer \u2013 clinical challenges and opportunities.","volume":"118","author":"Brown","year":"2023","journal-title":"Br J Cancer"},{"key":"R22-20260514","first-page":"129","article-title":"The immune microenvironment in pancreatic cancer.","volume":"11","author":"Johnson","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"R23-20260514","first-page":"1123","article-title":"An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer.","volume":"24","author":"Doe","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"R24-20260514","first-page":"1","article-title":"FDA approves pembrolizumab for advanced pancreatic cancer.","volume":"9","year":"2018","journal-title":"FDA News Release"},{"key":"R25-20260514","first-page":"405","article-title":"Overcoming immunosuppression and stromal barriers in pancreatic cancer.","volume":"15","author":"Wang","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R26-20260514","first-page":"123","article-title":"Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies.","volume":"40","author":"Johnson","year":"2023","journal-title":"J Immunother"},{"key":"R27-20260514","first-page":"1800","article-title":"Immune checkpoint inhibitors in combination with other therapies for advanced solid tumors.","volume":"35","author":"Doe","year":"2023","journal-title":"J Clin Oncol"},{"key":"R28-20260514","first-page":"102201","article-title":"Immunotherapy for pancreatic cancer: a 2020 update.","volume":"88","author":"Schizas","year":"2020","journal-title":"Cancer Treat Rev"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:06:58Z","timestamp":1778756818000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":27,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046077","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"2024-04-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}